ESICM News

SEPSIS & ACUTE LUNG INJURY

SEPSIS & ACUTE LUNG INJURY

SIX CLINICAL TRIAL RESULTS

Results from no fewer than six RCTs including a large-scale, global, mega-cohort study will be presented in this second special Thematic Session at LIVES 2014. Many of these clinical trials will have a discernible impact on clinical practice in the ICU, and inspire future research. This leading-edge session begins with the MEDUSA study.

Medical education for sepsis source control and antibiotics: The MEDUSA study 

MEDUSA is a cluster-randomised study funded by the German Government. ICUs of the intervention group received a multifaceted training regarding timing and kind of initial antiinfectious measures in patients with severe sepsis or septic shock. ICUs of the control group received standardised lectures regarding primary sepsis care. There was only a small drop in time to antibiotics and no improvement in 28 day mortality in the intervention group. The intervention was associated with a greater compliance to guidelines regarding blood culture management.

In his presentation, Frank Bloos concludes that multifaceted training regarding initial antiinfectious measures in sepsis was not superior to standard CME in terms of outcome. The correlation between time to antimicrobial therapy and mortality was significantly lower than expected.

"Rapid initiation of therapy is mandatory in patients with severe sepsis or septic shock, but achieving time to antibiotics of less than 2 hours likely has little effect on outcome." Frank Bloos


Understanding the global impact of acute respiratory failure. The LUNG-SAFE study

Preliminary results from the LUNG-SAFE study (Large observational study to UNderstand the Global impact of Severe Acute respiratoryFailurE) will also be presented during this session. LUNG-SAFE is a prospective, observational, 4-week inception cohort study that was carried out by the Acute Respiratory Failure section of ESICM 

The aim of this study was to prospectively assess the burden of, management and therapeutic approaches to, and outcomes from acute severe hypoxaemic respiratory failure requiring ventilatory support, during the winter months in both the northern and southern hemispheres. This study examines the contribution of ARDS as defined by the Berlin Definition to the burden of hypoxaemic respiratory failure. 

Over 500 ICUs from more than 50 counties around the globe have participated in the LUNG-SAFE study. More than 10,000 patients have been enrolled during the recruitment windows in the northern and southern hemispheres, of which approximately 4000 developed severe acute respiratory failure. 

"Data from the LUNG-SAFE study will provide us with a comprehensive and ‘real life’ picture of patients with severe acute respiratory failure across the globe in the 21st century." John Laffey 

The first presentation of data from LUNG-SAFE during this special session at LIVES 2014 in Barcelona will include an initial analysis of the data from the patients recruited from the northern Hemisphere.

Data from the LUNG-SAFE study will provide us with a comprehensive and ‘real life’ picture of patients with severe acute respiratory failure across the globe in the 21st century. This study will give us an unparalleled insight into severe acute respiratory failure, and its varied causes including ARDS, the different management strategies we use to treat these patients, and the outcome of patients suffering from these devastating conditions. 

Lead investigators from four other long-awaited clinical trials will present results in this unmissable session:

  • Sepsis pathophysiological & organisational timing: The SPOT(Light) study - Steve Harris (London, United Kingdom)
  • Placebo controlled trial of sodium selenite and procalcitonin guided antimicrobial therapy in severe sepsis (SISPCT) Konrad Reinhart (Jena, Germany)
  • Clinical effect of the association of noninvasive ventilation & high flow nasal oxygen therapy in resuscitation of patients with acute lung injury: The FLORALI study - Jean-Pierre Frat (Poitiers, France)
  • HMG-CoA reductase inhibition with simvastatin in ARDS to Reduce Pulmonary dysfunction (HARP-2) trial: A randomised controlled trial - Danny McAuley (Belfast, Ireland)

This Thematic Session is chaired by Derek Angus and Massimo Antonelli, and following each presentation, presenters are available for questions and discussion about their trials. Do not miss this unique opportunity to interact with these top researchers!


Thematic Session ~ CLINICAL TRIALS IN THE ICU - SEPSIS & ACUTE LUNG INJURY

30.09.2014, 16:00 – 18:00 - room Barcelona

<Back to the news list
Comment on this news Comment on this news
To respond to this article, thank you for identifying
ReactionsReactions (0)